PlainPill

S-23

The short answer. People are split on S-23 — 54% of 34 say it helped. It is most often used for performance: 93% of 29 reports say that improved. It is well studied — 6 meta-analyses on PubMed. The most common complaint is suppression. It is not an approved supplement and carries real risks.

What users report
54%helped34 reports · medium confidence
18 helped10 mixed6 didn't help

From 83 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
6
meta-analyses
26
RCTs
508
papers
High-risk compound. SARMs are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.

What S-23 does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 6 meta-analyses on PubMed ↗ · 26 randomized trials ↗

Surg Obes Relat Dis · 2025 · Meta-analysis / systematic review
Association between metabolic and bariatric surgery and malignancy: a systematic review, meta-analysis, trends, and conclusions

Conclusion: According to the data retrieved from patients who underwent MBS compared to nonoperated patients suffering from obesity, the overall risk for malignancy was lower in the MBS group. Additional information collected in this study revealed the behavior of specific types of cancer in response to induced weight loss by operative means. The benefit of surgery in patients suffering from obesity is not restricted to the improvement of obesity morbidity alone.

PubMed 39581814 ↗
J Affect Disord · 2016 · Meta-analysis / systematic review
Characteristics and heterogeneity of schizoaffective disorder compared with unipolar depression and schizophrenia - a systematic literature review and meta-analysis

Conclusion: Regarding unipolar affective disorder this study confirms what we have shown for bipolar disorders in earlier studies: schizoaffective disorder falls between schizophrenia and affective disorders, and there are relevant quantitative differences in key illness characteristics, which supports the validity of the schizoaffective disorder concept. Contrary to our expectations heterogeneity is not larger in SAD than in UD and not substantially higher than in S. Lower reliability of the diagnosis of SAD therefore cannot be ascribed to higher variability of illness characteristics in SAD.

PubMed 26599364 ↗
Registered clinical trials

4 human trials on ClinicalTrials.gov test S-23, 2 recruiting now. See all on ClinicalTrials.gov ↗

Dosage people report

We don't list doses for unapproved research compounds. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

suppression ×19acne ×3hair loss ×3aggression ×2night sweats ×2fatigue ×2

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“It personally was my favorite cycle. The strength and size gains were better than RAD.”
HelpedRead the discussion ↗
“S-23 is very strong but the side effects suck ass for a ton of people, some can use it fine but for others (like me) it has like tren level sides and simply isn't worth it.”
MixedRead the discussion ↗
“Really strong, be sure to have test base. Really acnee prone sarm. It felt like tren for me.”
MixedRead the discussion ↗
“I get amazing results from rad140 and almost none from s23 which is supposed to be one of the strongest.”
Didn't helpRead the discussion ↗
Read more S-23 reviews →
Top discussions (5)

Other options for performance

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate